Boston Partner Roger Lane was quoted in a July 9, 2013 Law360 article titled “Pain Now or Later? Thermo Fisher Tastes Earnout Bitters.” The article discusses how earnouts often result in infighting rather than bridging the gap between what sellers want and what buyers are willing to pay for unproven assets-something Thermo Fisher Scientific Inc. is finding out. Mr. Lane, a member of Foley’s Emerging Technologies Industry Team, was quoted saying, “Most buyers are reluctant to make guarantees about budgets or staffing levels. Often a seller’s best hope is a negative covenant, where the buyer promises not to do anything to undermine the seller’s efforts.” Mr. Lane also stated, “You can’t anticipate everything. You handicap the deal the best you can, and you live with it … especially when the alternative is that there is no deal.” But “at the end of the day, terms like that mean different things to different people, in light of circumstances that may have changed,” Mr. Lane said. “That’s most often what the litigation comes down to – interpreting the terms you spend all that time hammering out.”
Related News
27 November 2024
In the News
Lawrence Kraus Describes Loper Bright's Impact on False Claims Cases
Foley & Lardner LLP partner Lawrence Kraus is quoted in the Relias Media article, "Loper Bright Starting to Affect False Claims Cases."
26 November 2024
In the News
David Rosen on FDA GLP-1 Legal Battle – 'It's a precedent in this area'
Foley & Lardner LLP partner David Rosen described the legal battle between compounding pharmacies and the U.S. Food and Drug Administration over GLP-1 drugs in the BioSpace article, "Legal Challenge Over Lilly’s GLP-1 Shortages Highlights FDA’s Post-Chevron Vulnerability."
26 November 2024
In the News
Sara Abarbanel and Jacqueline Hayduk Assess Best Practices for Employee Assistance Programs
Employee assistance programs have become an extremely common benefit offered by U.S. employers.